회사 개요
Agilon Health, Inc. operates within the healthcare sector, specifically targeting the medical care facilities industry by providing essential healthcare services to senior populations across the United States. The firm utilizes a subscription-based model, often referred to as per-member per-month, to manage the comprehensive healthcare needs of its patient base through primary care physicians embedded in local communities. This operational approach positions the company as a significant player in the senior care infrastructure, with a total market capitalization of $329.46 million and annual revenue reaching $5.93 billion over the trailing twelve months. The entity employs a workforce of 856 individuals, indicating a substantial organizational scale that supports its extensive network of primary care delivery. Despite the relatively modest market cap compared to its revenue base, the financial metrics suggest a company that is currently prioritizing expansion and service delivery over immediate profitability, a common characteristic in capital-intensive healthcare facility operations where long-term value creation is expected to materialize as market share grows.
재무 건전성
The company reported revenue of $5.93 billion, yet recorded a net loss of $405,347,008, highlighting a significant gap between top-line sales and bottom-line earnings that reveals a heavy cost structure typical of early-stage scaling in healthcare services. This substantial net loss corresponds closely with an EBITDA of $-406,182,016, suggesting that operating expenses, including depreciation and amortization, are currently outweighing operational cash generation from services rendered. The free cash flow stands at $-81,226,128, which indicates a negative cash conversion cycle where cash outflows for operations and capital expenditures exceed cash inflows, thereby limiting the company's immediate financial flexibility for organic growth without external financing. All three margin metrics reflect this challenging profitability environment, with a gross margin of -2.7%, an operating margin of -10.0%, and a profit margin of -6.6%, signaling that the company is not yet achieving economies of scale necessary to cover its variable and fixed costs efficiently. On the balance sheet, the company holds $285.14 million in cash against $36.81 million in debt, resulting in a debt-to-equity ratio of 29.05, which suggests a highly leveraged position relative to equity but one supported by a significant cash buffer that mitigates immediate solvency risks. The current ratio of 1.02 further indicates a tight liquidity situation where current assets barely cover current liabilities, requiring careful management of working capital to avoid cash flow disruptions. Return on Equity is reported at -135.6% and Return on Assets at -17.5%, metrics that reveal management is currently unable to generate positive returns on the capital invested or assets utilized, reflecting the aggressive reinvestment phase rather than a mature profit-generating stage.
밸류에이션 평가
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to the lack of positive earnings and a forward P/E of -5.42, which implies that the market is pricing in future earnings recovery rather than current profitability. The price-to-book ratio of 2.60 suggests that the market is valuing the company at a significant premium over its net book value, potentially reflecting high growth expectations or intangible asset value not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.06 and an EV/EBITDA of -0.20, which indicate that the stock is trading at a fraction of its sales revenue, a scenario often seen in distressed or turnaround situations where revenue growth is the primary driver of value. The stock has experienced extreme volatility, trading between a 52-week high of $152.00 and a 52-week low of $7.48, meaning the current price sits significantly below the recent peak but also indicates a wide trading range that reflects high uncertainty in earnings trajectory. The beta value of 0.33 suggests that the stock's price volatility is substantially lower than the broader market, as a beta less than 1.0 implies that the stock tends to move less than the overall market index during periods of economic fluctuation.
Growth & Income
Revenue growth stands at 3.1% year-over-year, while earnings growth is N/A due to the absence of positive earnings, indicating that top-line expansion is the sole focus while profitability remains elusive. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it is clear that the firm is reinvesting all available resources and retained earnings back into the business to fund operations, pay down debt, or pursue strategic acquisitions rather than distributing income to shareholders. This zero payout ratio is sustainable in the context of current losses but limits income generation for investors seeking yield, forcing reliance on capital appreciation driven by the 3.1% revenue expansion. Overall, the growth and income profile is characterized by modest revenue expansion coupled with a complete absence of dividend income and negative earnings, defining a high-risk, high-potential growth trajectory typical of healthcare facilities still navigating the path to profitability.